Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to diabetic macular edema: 12-month results from the 36-month BOREAL-DME study

被引：0
|
作者：
Garcher, Catherine P. Creuzot [1 ]
Massin, Pascale [2 ]
Kodjikian, Laurent [3 ]
Girmens, Jean-Francois [4 ]
DelCourt, Cecile [5 ]
Fajnkuchen, Frank [6 ]
Glacet, Agnes [7 ]
Guillausseau, Pierre-Jean [8 ]
Derveloy, Audrey [9 ]
Finzi, Laetitia [9 ]
Blin, Patrick [10 ]
机构：
[1] Univ Hosp, Ophthalmol, Dijon, France
[2] Hop Lariboisiere, Ophthalmol, Paris, France
[3] Hop Croix Rousse, Ophthalmol, Lyon, France
[4] CHNO Quinze Vingts, Ophthalmol, Paris, France
[5] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, INSERM, U1219, Bordeaux, France
[6] Hop Avicenne, Ophthalmol, Bobigny, France
[7] Ctr Hosp Intercommunal Creteil, Ophthalmol, Creteil, France
[8] Hop Lariboisiere, Internal Med, Paris, France
[9] Novartis Pharma SAS, Rueil Malmaison, Malmaison, France
[10] CIC Bordeaux, CIC1401, Dept Med Pharmacol, Bordeaux, France
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2017年 / 58卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
1915
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study
    Massin, Pascale
    Creuzot-Garcher, Catherine
    Kodjikian, Laurent
    Girmens, Jean-Francois
    Delcourt, Cecile
    Fajnkuchen, Frank
    Glacet-Bernard, Agnes
    Guillausseau, Pierre-Jean
    Ponthieux, Anne
    Blin, Patrick
    Grelaud, Angela
    [J]. OPHTHALMIC RESEARCH, 2019, 62 (02) : 101 - 110
  • [2] Real-World Outcomes after 36-Month Treatment with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema (BOREAL-DME)
    Massin, Pascale
    Creuzot-Garcher, Catherine
    Kodjikian, Laurent
    Girmens, Jean-Francois
    Delcourt, Cecile
    Fajnkuchen, Franck
    Glacet-Bernard, Agnes
    Guillausseau, Pierre-Jean
    Guthux, Francoise
    Blin, Patrick
    Grelaud, Angela
    [J]. OPHTHALMIC RESEARCH, 2021, 64 (04) : 577 - 586
  • [3] Real-world outcomes with ranibizumab 0.5 mg in treatment-naive French patients with visual impairment due to diabetic macular edema: 12-month results from the ETOILE study
    Fourmaux, Eric
    Lecleire-Collet, Amelie
    Dot, Corinne
    Le Lez, Marie-Laure
    Baillif, Stephanie
    Erginay, Ali
    Souied, Eric
    Gain, Philippe
    Kodjikian, Laurent
    Finzi, Laetitia
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [4] Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study
    Xiaoxin Li
    Hong Dai
    Xiaorong Li
    Mei Han
    Jun Li
    Andrea Suhner
    Renxin Lin
    Sebastian Wolf
    [J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257 : 529 - 541
  • [5] Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study
    Li, Xiaoxin
    Dai, Hong
    Li, Xiaorong
    Han, Mei
    Li, Jun
    Suhner, Andrea
    Lin, Renxin
    Wolf, Sebastian
    Li, Xiaoxin
    Qi, Huijun
    Tao, Ye
    Li, Yan
    Bai, Yujing
    Yin, Hong
    Liu, Guodong
    Han, Li
    Qian, Tong
    Huang, Lvzhen
    Miao, Heng
    Zhao, Mingwei
    Hou, Jing
    Cheng, Yong
    Liang, Jianhong
    Shi, Xuan
    Qu, Jinfeng
    Yu, Wenzhen
    Tao, Yong
    Chen, Yi
    Zhang, Feng
    Shi, Xuehui
    Gao, Liqin
    Ding, Ning
    Yang, Lihong
    Zhao, Shiqiang
    Yang, Qiong
    Shen, Rong
    Xiong, Ying
    Dong, Fangtian
    Zhang, Xiao
    Gong, Di
    Qu, Yi
    Dai, Fangfang
    He, Feng
    Han, Xiaoxu
    Dai, Rongping
    Du, Hong
    Yu, Weihong
    Li, Donghui
    Yang, Zhikun
    Ma, Zhizhong
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 257 (03) : 529 - 541
  • [6] Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to macular edema secondary to central retinal vein occlusion: 6-month results from the 24-month BOREAL-CRVO study
    Srour, Mayer
    Glacet, Agnes
    Girmens, Jean-Francois
    Kodjikian, Laurent
    DelCourt, Cecile
    Fajnkuchen, Frank
    Garcher, Catherine P. Creuzot
    Massin, Pascale
    Guillausseau, Pierre-Jean
    Ponthieux, Anne
    Finzi, Laetitia
    Grelaud-Boussinot, Angela
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [7] Real-world outcomes of ranibizumab treatment in French patients with visual impairment due to Macular Edema secondary to Retinal Vein Occlusion: 24-month results from the BOREAL-RVO study.
    Glacet-Bernard, Agnes
    Girmens, Jean-Francois
    Kodjikian, Laurent
    Delcourt, Cecile
    Fajnkuchen, Franck
    Creuzot-Garcher, Catherine
    Massin, Pascale
    San Nicolas, Nathalie
    [J]. OPHTHALMIC RESEARCH, 2023, 66 (01) : 824 - 834
  • [8] Ranibizumab 0.5 mg in Asian patients with visual impairment due to macular edema secondary to central retinal vein occlusion: results from the 12-month CAMELLIA study
    Ma, Zhizhong
    Zhu, Liansheng
    Weisberger, Annemarie
    Cheng, Yu
    Liu, Chang
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [9] ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema
    Kodjikian, Laurent
    Lecleire-Collet, Amelie
    Dot, Corinne
    Le Lez, Marie-Laure
    Baillif, Stephanie
    Erginay, Ali
    Souied, Eric
    Fourmaux, Eric
    Gain, Philippe
    Ponthieux, Anne
    [J]. CLINICAL OPHTHALMOLOGY, 2021, 15 : 2307 - 2315
  • [10] Efficacy and safety of ranibizumab 0.5 mg in Asian patients with visual impairment due to macular edema secondary to branch retinal vein occlusion: results from the 12-month BLOSSOM study
    Wei, Wenbin
    Zhu, Liansheng
    Weisberger, Annemarie
    Cheng, Yu
    Liu, Chang
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
12345